Obesity Surgery

, Volume 19, Issue 3, pp 345–350 | Cite as

Regulation of Bone Mineral Density in Morbidly Obese Women: A Cross-sectional Study in Two Cohorts Before and After Bypass Surgery

  • José Manuel GómezEmail author
  • Núria Vilarrasa
  • Carles Masdevall
  • Jordi Pujol
  • Esther Solano
  • Juan Soler
  • Iñaki Elio
  • Lluis Gallart
  • Joan Vendrell
Research Article



The mechanisms by which increased body weight influence bone mass density (BMD) are still unknown. The aim of our study was to analyze the relationship between anthropometric and body composition variables, insulin growth factor-I (IGF-I), adiponectin and soluble tumor necrosis factor-α receptors (sTNFR) 1 and 2 with BMD in two cohorts of morbid obese patients, before and after bypass surgery.


The first cohort included 25 women aged 48 ± 7.6 years studied before bypass surgery. The second included 41 women aged 46 ± 9.2 years, 12 months after surgery. We studied anthropometric variables obtained from whole body DEXA composition analysis. Serum IGF-I, intact serum parathyroid hormone, 25-hydroxivitamin D3, plasma adiponectin concentrations, sTNFR1, sTNFR2 concentrations were measured.


In the first cohort, the BMI was 44.5 ± 3.6 kg/m2, parathyroid hormone, IGF-I, and adiponectin concentrations were lower, and sTNFR1 concentrations were higher than in the second cohort. In the multiple regression analysis, BMD remained significantly associated with body fat percentage (β −0.154, p = 0.01), lean mass (β 0.057, p = 0.016) and phosphate concentration (β 0.225, p = 0.05). In the second cohort, BMI was 31 ± 5.1 kg/m2. In the multiple regression analysis, BMD remained significantly associated with lean mass (β 0.006, p = 0.03).


The inverse correlation found between body fat and BMD in the first cohort indicates morbid obesity increases the risk of osteoporosis and we found a positive correlation with lean and fat mass before bariatric surgery and with lean mass after bypass surgery.


Adiponectin Bone mineral density Insulin growth factor-I Morbid obesity Parathyroid hormone 25-hydroxivitamin D3 Soluble tumor necrosis factor-α receptor-1 Soluble tumor necrosis factor-α-2 


  1. 1.
    Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausic women. J Clin Endocrinol Metab. 1993;77:683–6.PubMedGoogle Scholar
  2. 2.
    Morberg CM, Tetens I, Black E, et al. Leptin and bone mineral density: a cross-sectional study in obese and non obese men. J Clin Endocrinol Metab. 2003;88:5795–800.CrossRefGoogle Scholar
  3. 3.
    Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60:329–39.CrossRefGoogle Scholar
  4. 4.
    Kleerekoper M, Nelson DA, Peterson EL, et al. Body composition and gonadal steroids in older white and black women. J Clin Endocrinol Metab. 1994;79:775–9.PubMedGoogle Scholar
  5. 5.
    Reid D, Evans M, Cooper G, et al. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 1993;265:293–7.Google Scholar
  6. 6.
    Gómez JM. Sex and age differences in serum leptin, insulin-like growth factor-I components and sex-hormone binding globulin in a healthy population. Prot Pept Lett. 2007;14:708–11.CrossRefGoogle Scholar
  7. 7.
    Gómez JM, Maravall FJ, Gómez N, et al. The IGF-I system component concentration that decrease with ageing are lower in obesity in relationship to body mass index and body fat. Growth Horm & IGF Res. 2004;14:91–6.CrossRefGoogle Scholar
  8. 8.
    Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin and proinflammatory cytokines: relationships in obesity. Obes Surg. 2004;12:962–71.Google Scholar
  9. 9.
    Vilarrasa N, Vendrell J, Maravall J, et al. Distribution and determinants of adiponectin, resistin and ghrelin in randomly selected healthy population. Relationship with IGF-I system. Clin Endocrinol (Oxf). 2005;63:329–35.CrossRefGoogle Scholar
  10. 10.
    Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293–300.CrossRefGoogle Scholar
  11. 11.
    Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.CrossRefGoogle Scholar
  12. 12.
    Wood IS, Wang B, Jenkins JR, Trayhurn P. The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNF alpha in human adipocytes. Biochem Biophys Res Commun. 2005;337:422–9.CrossRefGoogle Scholar
  13. 13.
    Hamrick MW, Pennington C, Newton D, et al. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 2004;34:376–83.CrossRefGoogle Scholar
  14. 14.
    Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.CrossRefGoogle Scholar
  15. 15.
    Straczkowski M, Kowalska I, Nikolajuk A, et al. Increased serum interleukin-18 is associated with hypoadiponectinemia in obesity, independently of insulin resistance. Intern J Obes. 2006;31:221–5.CrossRefGoogle Scholar
  16. 16.
    Lenchik L, Register TC, Hsu F-C, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33:646–51.CrossRefGoogle Scholar
  17. 17.
    Oh KW, Lee WY, Rhee EJ, et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf). 2005;63:131–8.CrossRefGoogle Scholar
  18. 18.
    Sambrook P. Tumor necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther. 2007;9:107.CrossRefGoogle Scholar
  19. 19.
    Capella RF, Capella JF. Reducing early technical complications in gastric by-pass surgery. Obes Surg. 1997;7:149–57.CrossRefGoogle Scholar
  20. 20.
    Molina A, Vendrell J, Gutiérrez C, et al. Insulin resistance, leptin and TNF-α system in obese morbid women after gastric bypass surgery. Obes Surg. 2003;13:615–21.CrossRefGoogle Scholar
  21. 21.
    Gómez JM, Maravall FJ, Gómez N, et al. 25-(OH) D3 regulation in a healthy population randomly selected. Horm Metab Res. 2004;36:48–53.CrossRefGoogle Scholar
  22. 22.
    Gómez JM. The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biothec. 2006;7:125–32.CrossRefGoogle Scholar
  23. 23.
    World Health Organization. Obesity: preventing and managing the global epidemic. Report on a WHO consultation on obesity. WHO/NUT/NCD/98.1. Geneva: WHO, 3–5 June, 1997.Google Scholar
  24. 24.
    El-Kadre LJ, Rocha PR, de Almeida Tinoco AC, et al. Calcium metabolism in pre- and postmenopausal morbidly obese women at baseline and after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2005;14:1062–6.CrossRefGoogle Scholar
  25. 25.
    Ybarra J, Sánchez-Hernández I, Gich T, et al. Unchanged hypovitaminosis D and secondary hyperparathyroidism in morbid obesity after bariatric surgery. Obes Surg. 2005;15:330–5.CrossRefGoogle Scholar
  26. 26.
    Goode LR, Brolin RE, Chowdhury HA, et al. Bone and gastric bypass surgery: effects of dietary calcium and vitamin D. Obes Res. 2004;12:40–7.CrossRefGoogle Scholar
  27. 27.
    Maeda K, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, and adipose-derived protein. Diabetes. 2001;50:2094–9.CrossRefGoogle Scholar
  28. 28.
    Vilarrasa N, Vendrell J, Sánchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumor necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf). 2007;67:679–86.CrossRefGoogle Scholar
  29. 29.
    Kontogianni MD, Dafni UG, Routsias JG, et al. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res. 2004;19:546–51.CrossRefGoogle Scholar
  30. 30.
    Seriolo B, Paolino S, Sulli A, et al. Bone metabolism exchanges during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:420–7.CrossRefGoogle Scholar
  31. 31.
    Santos JL, Lera L, Pérez-Bravo F, et al. Adiposity and bone mineral density of Chilean elderly women in relation to toll-like receptor 4 gene polymorphisms. Ann Hum Biol. 2006;33:585–92.CrossRefGoogle Scholar
  32. 32.
    Núñez NP, Carpenter CL, Perkins SN, et al. Extreme obesity reduces bone mineral density: complementary evidence from mice and women. Obesity. 2007;15:1980–7.CrossRefGoogle Scholar
  33. 33.
    Edelstein SL, Barrett-Connor E. Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol. 1993;138:160–9.CrossRefGoogle Scholar
  34. 34.
    Reid I, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab. 1992;75:779–82.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • José Manuel Gómez
    • 1
    Email author
  • Núria Vilarrasa
    • 1
  • Carles Masdevall
    • 2
  • Jordi Pujol
    • 2
  • Esther Solano
    • 3
  • Juan Soler
    • 1
  • Iñaki Elio
    • 1
  • Lluis Gallart
    • 3
  • Joan Vendrell
    • 3
  1. 1.CIBERDEM, Endocrinology ServiceHospital Universitario de Bellvitge, L’Hospitalet de LlobregatBarcelonaSpain
  2. 2.Department of SurgeryHospital Universitario de BellvitgeBarcelonaSpain
  3. 3.CIBERDEM, Endocrinology ServiceHospital Universitario Joan XXIIITarragonaSpain

Personalised recommendations